R Squared Ltd Makes New $202,000 Investment in Sanofi (NASDAQ:SNY)

R Squared Ltd acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,180 shares of the company’s stock, valued at approximately $202,000.

A number of other large investors have also modified their holdings of the company. Northwest Investment Counselors LLC bought a new stake in shares of Sanofi in the 3rd quarter valued at approximately $29,000. Concord Wealth Partners boosted its stake in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares in the last quarter. Fortitude Family Office LLC grew its position in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares during the period. Sunbelt Securities Inc. lifted its holdings in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the period. Finally, Versant Capital Management Inc bought a new position in shares of Sanofi during the fourth quarter valued at $54,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Down 1.1 %

SNY stock opened at $52.37 on Thursday. The business has a fifty day moving average price of $48.99 and a 200 day moving average price of $52.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a market capitalization of $132.92 billion, a price-to-earnings ratio of 26.72, a P/E/G ratio of 1.19 and a beta of 0.57.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.